An integrated genome-wide approach to discover tumor-specific antigens as potential immunologic and clinical targets in cancer

Cancer Research

Volumn 72, Issue 24, 2012, Pages 6351-6361

  Xu, Qing Wen ^a   Zhao, Wei ^a   Wang, Yue ^h   Sartor, Maureen A ⁱ   Han, Dong Mei ^b   Deng, Jixin ^h   Ponnala, Rakesh ^h   Yang, Jiang Ying ^c   Zhang, Qing Yun ^c   Liao, Guo Qing ^d   Qu, Yi Mei ^d   Li, Lu ^e   Liu, Fang Fang ^f   Zhao, Hong Mei ^g   Yin, Yan Hui ^a   Chen, Wei Feng ^a   Zhang, Yu ^a   Wang, Xiao Song ^h  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b AIR FORCE GENERAL HOSPITAL   (China)

^c PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^d 309TH HOSPITAL OF PLA   (China)

^e 306 HOSPITAL OF PLA   (China)

^f PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^g PEKING UNIVERSITY THIRD HOSPITAL   (China)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

ⁱ UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; TUMOR ANTIGEN;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CANCER CELL; CANCER GENETICS; CANCER IMMUNOLOGY; COHORT ANALYSIS; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE TARGETING; GENETIC ASSOCIATION; HETEROGENEOUS EXPRESSION PROFILE ANALYSIS; HUMAN; HUMAN GENOME; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN A/G BASED REVERSE SEROLOGICAL EVALUATION; PROTEIN DETERMINATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; TSA GENE;

ANTIGENS, NEOPLASM; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ASSOCIATION STUDIES; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HUMANS; IMMUNOTHERAPY; MALE; MICROARRAY ANALYSIS; MOLECULAR TARGETED THERAPY; NEOPLASMS; ORGAN SPECIFICITY; SYSTEMS INTEGRATION;

EID: 84871215951     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-1656     Document Type: Article

References (42)

1. Crawford ED, Grubb R III, Black A, Andriole GL Jr, Chen MH, Izmirlian G, et al. Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol 2011;29:355-61.
2. Gebo KA, Chander G, Jenckes MW, Ghanem KG, Herlong HF, Torbenson MS, et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology 2002;36:S84-92. (Pubitemid 35253467)
3. Berger AC, GarciaMJr,Hoffman JP, Regine WF, Abrams RA, Safran H, et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 2008;26:5918-22.
4. Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005;353:1224-35. (Pubitemid 41345944)
5. Qiu J, Hanash S. Autoantibody profiling for cancer detection. Clin Lab Med 2009;29:31-46.
6. Ludwig N, Keller A, Comtesse N, Rheinheimer S, Pallasch C, Fischer U, et al. Pattern of serum autoantibodies allows accurate distinction between a tumor and pathologies of the same organ. Clin Cancer Res 2008;14:4767-74.
7. Tan HT, Low J, Lim SG, Chung MC. Serum autoantibodies as biomarkers for early cancer detection. FEBS J 2009;276:6880-904.
8. Leidinger P, Keller A, Ludwig N, Rheinheimer S, Hamacher J, Huwer H, et al. Toward an early diagnosis of lung cancer: an autoantibody signature for squamous cell lung carcinoma. Int J Cancer 2008;123:1631-6.
9. Finn OJ. Cancer immunology. N Engl J Med 2008;358:2704-15.
10. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8:299-308. (Pubitemid 351430867)
11. Melief CJ, van der Burg SH. Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008;8:351-60. (Pubitemid 351589701)
12. Fontana R, Bregni M, Cipponi A, Raccosta L, Rainelli C, Maggioni D, et al. Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients. Blood 2009;113:1651-60.
13. Adams S, O'Neill DW, Nonaka D, Hardin E, Chiriboga L, Siu K, et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 2008;181:776-84.
14. Butterfield LH, Comin-Anduix B, Vujanovic L, Lee Y, Dissette VB, Yang JQ, et al. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother 2008;31:294-309. (Pubitemid 351441001)
15. Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 2011;17:3520-6.
16. Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, Schwartz M, et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007;45:938-47. (Pubitemid 46646500)
17. Piccaluga PP, Agostinelli C, Califano A, Rossi M, Basso K, Zupo S, et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest 2007;117:823-34. (Pubitemid 46348541)
18. Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 2007;7:233-45. (Pubitemid 46480968)
19. Pruitt KD, Harrow J, Harte RA, Wallin C, Diekhans M, Maglott DR, et al. The consensus coding sequence (CCDS) project: identifying a common protein-coding gene set for the human and mouse genomes. Genome Res 2009;19:1316-23.
20. Hollander M, Wolfe DA. Nonparametric statistical methods. 2nd ed. New York: Wiley; 1999. p. 178.
21. Yin YH, Li YY, Qiao H, Wang HC, Yang XA, Zhang HG, et al. TSPY is a cancer testis antigen expressed in human hepatocellular carcinoma. Br J Cancer 2005;93:458-63. (Pubitemid 43080021)
22. Liu FF, Dong XY, Pang XW, Xing Q, Wang HC, Zhang HG, et al. The specific immune response to tumor antigen CP1 and its correlation with improved survival in colon cancer patients. Gastroenterology 2008;134:998-1006. (Pubitemid 351451976)
23. Butterfield LH, Ribas A, Dissette VB, Lee Y, Yang JQ, De la Rocha P, et al. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res 2006;12:2817-25.
24. McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol 2009;27:4047-54.
25. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089-94. (Pubitemid 46638945)
26. Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005;11:3353-62. (Pubitemid 40627887)
27. Di Pucchio T, Pilla L, Capone I, Ferrantini M, Montefiore E, Urbani F, et al. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res 2006;66:4943-51.
28. Chianese-Bullock KA, Pressley J, Garbee C, Hibbitts S, Murphy C, Yamshchikov G, et al. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. J Immunol 2005;174:3080-6. (Pubitemid 40279730)
29. Lindsey KR, Gritz L, Sherry R, Abati A, Fetsch PA, Goldfeder LC, et al. Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma. Clin Cancer Res 2006;12:2526-37.
30. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005;5:615-25. (Pubitemid 41081387)
31. Vaudin P, Delanoue R, Davidson I, Silber J, Zider A. TONDU (TDU), a novel human protein related to the product of vestigial (vg) gene of Drosophila melanogaster interacts with vertebrate TEF factors and substitutes for Vg function in wing formation. Development 1999;126:4807-16.
32. Worby CA, Dixon JE. Sorting out the cellular functions of sorting nexins. Nat Rev Mol Cell Biol 2002;3:919-31. (Pubitemid 35477370)
33. Anton RF, Voronin KK, Randall PK, Myrick H, Tiffany A. Naltrexone modification of drinking effects in a subacute treatment and Bar-Lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes. Alcohol Clin Exp Res 2012;36:2000-7.
34. Lee HJ, Nam KT, Park HS, Kim MA, Lafleur BJ, Aburatani H, et al. Gene expression profiling of metaplastic lineages identifies CDH17 as a prognostic marker in early stage gastric cancer. Gastroenterology 2010;139:213-25.
35. Auf FA, El-Eibdy GK, Mosaad YM, El-Ghannam DM, El-Masry EE. Cytokeratin 20 and vascular endothelial growth factor as molecular markers in Egyptian patients with colorectal cancer. J Oncol Pharm Pract 2011;17:160-7.
36. Moon JH, Fujiwara Y, Nakamura Y, Okada K, Hanada H, Sakakura C, et al. REGIV as a potential biomarker for peritoneal dissemination in gastric adenocarcinoma. J Surg Oncol 2012;105:189-94.
37. Hayes DC, Secrist H, Bangur CS, Wang T, Zhang X, Harlan D, et al. Multigene real-time PCR detection of circulating tumor cells in peripheral blood of lung cancer patients. Anticancer Res 2006;26:1567-75.
38. Yoneda K, Iida H, Endo H, Hosono K, Akiyama T, Takahashi H, et al. Identification of Cystatin SN as a novel tumor marker for colorectal cancer. Int J Oncol 2009;35:33-40.
39. Marin-Aguilera M, Mengual L, Ribal MJ, Ars E, Rios J, Gazquez C, et al. Utility of urothelial mRNA markers in blood for staging and monitoring bladder cancer. Urology 2012;79:240.
40. Adam PJ, Terrett JA, Steers G, Stockwin L, Loader JA, Fletcher GC, et al. CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding. Br J Cancer 2006;95:298-306. (Pubitemid 44187590)
41. Shantha Kumara H CM, Caballero OL, Tao S, Ahmed A, Cekic V, Gnjatic S, et al. T1635 Expression of the Cancer Testis Antigen IGF2BP3 (IMP3) in Colorectal Cancers; IMP3 Holds Promise as a Specific Immunotherapy Target. Gastroenterology 2010;138:S883-4.
42. Wang X, Zhao H, Xu Q, Jin W, Liu C, Zhang H, et al. HPtaa database-potential target genes for clinical diagnosis and immunotherapy of human carcinoma. Nucleic Acids Res 2006;34:D607-12.